1. Optimizing Outcomes in the Management of GIST

3. Introduction Gastrointestinal Stromal Tumor (GIST)

4. KIT Mutations in GIST

5. Challenges of Treating Advanced Disease

6. Case Study: Advanced GIST

7. Resistance to Imatinib

8. Mutational Testing

9. Imatinib for GIST

10. MetaGIST

11. Imatinib AEs (≥ 30% of Patients in Clinical Trials)

12. Combined Surgical and Molecular Therapy

13. Managing Imatinib Resistance

14. Sunitinib Phase 3 Trial

15. Correlation of Mutational Status With Clinical Benefit in GIST Treated With Sunitinib

16. Sunitinib AEs (≥ 20% of Patients in Clinical Trials)

17. Management of Select AEs

18. Continuous Daily Dosing of Sunitinib

19. Tools for Preventing and Managing AEs

20. Supporting Adherence

21. Regorafenib

22. GRID Trial Regorafenib

23. Regorafenib AEs (≥ 20% of Patients in Clinical Trials)

24. Secondary Mutations of Exon 17 and Response to Regorafenib

25. Managing Patients on Oral Medications

26. Fourth-Line Options

27. Why Has the Patient Progressed After Third-Line Options?

28. Ongoing Clinical Trials

29. Concluding Remarks

30. Abbreviations

31. Abbreviations (cont)